Skip to main content

Table 1 Clinical characteristics of patients

From: Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients

Characteristics

Training set(n = 155)

p

Validation set(n = 56)

p

Non-pCR(n = 94)

pCR(n = 61)

 

Non-pCR(n = 35)

pCR(n = 21)

 

Age

49.5(45.2,55.8)

49.0(46.0,54.0)

0.437

52.3 ± 9.63

50.3 ± 9.26

0.623

T stage (%)

  

0.149

  

0.420

 T1

4 (4.26)

3 (4.92)

 

3 (8.57)

0 (0.00)

 

 T2

64 (68.1)

47 (77.0)

 

23 (65.7)

18 (85.7)

 

 T3

10 (10.6)

8 (13.1)

 

5 (14.3)

2 (9.52)

 

 T4

16 (17.0)

3 (4.92)

 

4 (11.4)

1 (4.76)

 

N stage (%)

  

0.076

  

0.946

 N0

28 (29.8)

13 (21.3)

 

9 (25.7)

5 (23.8)

 

 N1

50 (53.2)

44 (72.1)

 

17 (48.6)

12 (57.1)

 

 N2

13 (13.8)

4 (6.56)

 

6 (17.1)

2 (9.52)

 

 N3

3 (3.19)

0 (0.00)

 

3 (8.57)

2 (9.52)

 

ER status (%)

  

0.03

  

0.128

 Negative

39 (41.5)

37 (60.7)

 

13 (37.1)

13 (61.9)

 

 Positive

55 (58.5)

24 (39.3)

 

22 (62.9)

8 (38.1)

 

PR status (%)

  

0.047

  

0.448

 Negative

30 (31.9)

30 (49.2)

 

15 (42.9)

12 (57.1)

 

 Positive

64 (68.1)

31 (50.8)

 

20 (57.1)

9 (42.9)

 

HER2 status (%)

  

 < 0.001

  

0.001

 Negative

69 (73.4)

22 (36.1)

 

25 (71.4)

5 (23.8)

 

 Positive

25 (26.6)

39 (63.9)

 

10 (28.6)

16 (76.2)

 

Ki-67 status (%)

  

0.238

  

1.000

  < 30%

26 (27.7)

11 (18.0)

 

8 (22.9)

5 (23.8)

 

  ≥ 30%

68 (72.3)

50 (82.0)

 

27 (77.1)

16 (76.2)

 
  1. Data in parentheses are percentages; p values were derived from the univariate analysis between each of characteristic and pCR Status. HER2 Human epidermal growth factor receptor 2, ER Estrogen receptor, PR Progesterone receptor